A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
We understand MS heat-sensitivity, and we know our products can help.
Many people living with MS experience heat intolerance. This can occur during the warmer summer months, after exercise or even while cooking in a hot kitchen! There has been extensive research on the cause and occurrence of heat intolerance in MS with studies dating back to the 1950's. (Seewww.MSCooling.info for a partial list.) When a person with MS experiences a rise in body temperature, nerve conduction may be slowed or even blocked which can cause a temporary worsening of MS related symptoms.
The effects are reported to be temporary with symptoms returning to their normal level as the body cools. Each person's MS is unique and so is how this heat affects individuals. However, if you experience intolerance to heat, it does not have to limit you!
Cooling garments are a major resource that can be used to help beat the heat. There are many types, technologies and styles of cooling garments that can help in a variety of situations.
Nov. 25, 2013,
Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzyme's Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch
More Neurologists Now Mention Once-Daily Dosing As Aubagio's Biggest Advantage Compared With Earlier in Launch, According to a New Report from BioTrends Research Group
EXTON, Pa., Nov. 25, 2013 /PRNewswire via COMTEX/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that two-thirds of surveyed U.S. neurologists have prescribed Genzyme's Aubagio, the second oral disease-modifying therapy (DMT) to reach the multiple sclerosis (MS) market, to at least one of their MS patients at one year post-launch. This increase in prescriber base represents a modest expansion compared with six months ago when Biogen Idec's Tecfidera, the third oral DMT to market, became commercially available. Neurologist-reported patient share for Aubagio among relapsing-remitting MS (RR-MS) patients treated with DMTs has also remained stable at two percent over the past six months. Reflecting increased product awareness and neurologist familiarity compared with earlier in the launch, significantly more surveyed neurologists now know that Aubagio is dosed once daily, providing a potential point of differentiation with recently launched, twice-daily Tecfidera. In fact, while Aubagio's oral formulation continues to be identified top-of-mind as the product's single biggest advantage compared with other currently available treatment options for MS, more surveyed neurologists now mention Aubagio's once-daily administration as its biggest advantage than at one, three, and six months post-launch. Continue Reading
To comment - click the comment link shown below
USE OUR SHARE LINKS at the top of this page - to provide this
article to others
is the main cause for permanent disability in multiple sclerosis. The effect of
current immunomodulatory treatments on neurodegeneration is insufficient.
Therefore, direct neuroprotection and myeloprotection remain an important
therapeutic goal. Targeting acid-sensing ion channel 1 (encoded by the ASIC1
gene), which contributes to the excessive intracellular accumulation of
injurious Na(+) and Ca(2+) and is over-expressed in acute multiple sclerosis
lesions, appears to be a viable strategy to limit cellular injury that is the
substrate of neurodegeneration.
(RTTNews.com) - Biogen Idec ( BIIB ) said Friday that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has determined that dimethyl fumarate in Tecfidera qualifies as a new active substance or NAS. The company noted that the designation will provide 10 years of regulatory exclusivity for Tecfidera in the European Union or EU.
The NAS determination follows a positive opinion by the CHMP in March 2013 recommending marketing authorization in the EU for Tecfidera as a first-line oral treatment for adults with relapsing-remitting multiple sclerosis or RRMS. The CHMP's determination will now be referred to the European Commission or EC, which grants marketing authorization for medicines in the EU, the company said.